When the Cure Works but Doesn't Heal

What's happening

A Cochrane review published April 16, analyzing 17 clinical trials and 20,342 participants, concluded that anti-amyloid Alzheimer's drugs produce cognitive benefits that are "absent or trivial," falling well below the minimum clinically important difference. The drugs, including lecanemab and donanemab, successfully remove amyloid plaques from the brain. The plaques clear. The patients do not improve. Meanwhile, brain swelling occurred in 119 per 1,000 treated patients versus 12 per 1,000 on placebo. Lecanemab costs $26,500 per year in the U.S., with total treatment costs reaching $82,500 per patient annually. The review has drawn sharp criticism from some researchers who argue it unfairly pooled five failed drugs with two approved ones. Approximately 57 million people live with Alzheimer's globally. For millions of families, these were the first treatments that promised to change the disease itself, rather than merely manage its symptoms.

What the Text says

Romans 8 contains Paul's most sustained reflection on the gap between what can be observed and what is hoped for. Writing to a community enduring real suffering, he makes a distinction that bears directly on this story.

Romans 8:24-2524For we were saved in hope, but hope that is seen is not hope. For who hopes for that which he sees?25But if we hope for that which we don't see, we wait for it with patience.

The Greek word translated "hope" is elpis, which in Paul's usage carries the weight of confident expectation, not wishful thinking. His argument is precise: hope that rests on what is already visible is no longer hope. The act of hoping requires that the outcome remain unseen.

This creates an unexpected frame for the Alzheimer's findings. The drugs produce something visible. The amyloid plaques dissolve. Brain scans confirm the biological change. But the visible change does not deliver what families actually hope for: recognition, presence, one more conversation where the person they love is still there. The seen result and the hoped-for result are not the same thing.

Paul does not counsel abandoning hope when the evidence is thin. He says the opposite. But he insists on a distinction the pharmaceutical framework cannot make: between a measurable outcome and a meaningful one.

The reflection

The deepest grief in Alzheimer's is not that the body fails. It is that the person leaves before the body does. A drug that clears plaques from the brain without restoring the person behind the eyes has answered the wrong question with extraordinary precision.

Families paying $82,500 a year are not purchasing a biological mechanism. They are purchasing time. The Cochrane data suggests they are not receiving it. What remains is the question every caregiver eventually faces alone: how to keep hoping when the evidence offers nothing to hold.